Back to News
Market Impact: 0.35
Ascendis Unveils $400 Mln Buyback; Regains TransCon Rights From Novo Nordisk
Source: Nasdaq
Capital Returns (Dividends / Buybacks)Healthcare & BiotechPatents & Intellectual Property
Ascendis Pharma's board authorized a share-repurchase program of up to $400 million. The commercial-stage biotech also said it will regain exclusive rights to develop, manufacture and commercialize TransCon technology-based products, strengthening its control over the platform and capital-return profile.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.40
Ticker Sentiment
ASND0.65
More News
- Tech giants need legacy businesses to keep growing as they pour trillions into the AI buildout
- Illumina CEO on Q3 Results and Business Outlook
- UnitedHealth is finally getting its act together. I'm buying into the turnaround
- Swiss Firms Plan Investment Boost in China Drug, Finance Sectors
- S&P cuts Meta outlook to negative amid capex concerns
- Parabolic Technologies receives Nasdaq delisting notice, shareholders approve share increase